Nov 18, 2020 / 10:35AM GMT
Christopher Lawrence Howerton - Jefferies LLC, Research Division - Equity Analyst
Hi, everyone. Thanks so much for joining us. My name is Chris Howerton, I'm part of the Jefferies biotechnology equity research team. Very pleased to be hosting a fireside chat with next company, Compugen. We're obviously joined by the team here, but including: Anat, the CEO; Ari, the CFO; Henry, the clinical development lead; and Eran, the earlier-stage R&D development lead. So thanks for joining us, everybody.
Questions and Answers:
Christopher Lawrence Howerton - Jefferies LLC, Research Division - Equity AnalystOkay. Great. So maybe before we get started in terms of your lead programs in immuno-oncology, I'll note to the audience out here that you actually have a pretty extensive and robust drug discovery platform. So Anat or Eran, I don't know who would like to take this question, but would love to just kind of hear a little bit about the platform and how it is that you have arrived at your current portfolio of assets.
Anat Cohen-
Trustpilot
